Navigation Links
FDA Clears Mandometer® for the Treatment of Eating Disorders
Date:4/6/2011

NEW YORK, April 6, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration announced on March 31 that it had cleared Mandometer® for the treatment of patients with eating disorders.  

Mandometer® is an innovative device that provides biofeedback allowing individuals to monitor their rate of eating and their development of satiety during meals and in comparison to those eating normally. Once patients learn to adapt to a normal eating pattern, they are able to normalize their body weight.

The device has been shown to be effective through randomized clinical trials for the treatment of eating disorders.  Those trials have demonstrated that 75 percent of the patients treated with the Mandometer® method recover and 90 percent remain healthy over five years.

This breakthrough program was developed by Cecilia Bergh, Ph.D., and Per Sodersten, Ph.D., two researchers at the world-renowned Swedish academic health center, the Karolinska Institute in Stockholm, Sweden.  

Dr. Bergh and Dr. Sodersten founded the company Mando Group AB to establish clinics that utilize the Mandometer® method to treat eating disorders. Currently, there are already Mandometer® clinics in Sweden, in Australia and one on East 78th Street in New York.  

As a result of the issue of the FDA clearance, physicians can prescribe therapy by the Mandometer® method.  

Cecilia Bergh is CEO of Mando Group AB and is also executive director of the Mandometer®  Clinics.  Per Sodersten is professor of Behavioral Neuroendocrinology at the Karolinska Institute.

To observe the Mandometer® being used, visit: http://www.mando.se/en/Media-archive--/Information-films--/Information-films-/1.aspx

To learn more about Mandometer® go to www.mandometer.com or www.mandonyc.com.

Cecilia Bergh and Per Sodersten are available for interviews via phone or video satellite.  


'/>"/>
SOURCE Mandometer
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
2. FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids
3. FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors
4. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
5. FDA Clears a Test for Ovarian Cancer
6. Private Investment Firm Czura Thornton Today Introduces Clearstone Central Laboratories as the Newest Member of the Czura Thornton Life Science Group
7. U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States
8. FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets
9. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
10. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
11. FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology scientists, Dr ... biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm ... on the ASX. Noxopharm is a clinic-ready company with ... 1 clinical study later this year. ... problems facing cancer patients - the ability of cancers to become ...
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology:
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, ... stem (iPS) cells and other difficult to transfect cells, announces its launch of ... PluriQ™ G9™ Gene Editing System is a complete system for culturing and ...
Breaking Medicine News(10 mins):